Pneumologie 2021; 75(S 01): S46-S47
DOI: 10.1055/s-0041-1723351
DOI: 10.1055/s-0041-1723351
Latebreaking Abstracts 2021
Efficacy ans safety of mepolizumab in hypereosinophilic syndrome: a Phase III, randomized, placebo-controlled trial
J Steinfeld
1
Respiratory Research & Development, Gsk, Collegeville, Pa, USA
,
F Roufosse
2
Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels,
Belgium
,
J E Kahn
3
Department of Internal Medicine, Hôpital Ambroise Paré, Université Versailles-Saint
Quentin-En-Yvelines, Boulogne-Billancourt, France
,
G J Gleich
4
School of Medicine, University of Utah, Salt Lake City, Ut, USA
,
M E Rothenberg
5
Division of Allergy and Immunology, Cincinnati Childrenʼs Hospital Medical Center,
and the Department of Pediatrics, University of Cincinnati, Cincinnati, Oh, USA
,
A J Wardlaw
6
Institute for Lung Health, University of Leicester, Leicester, UK
,
S Y Kirby
7
Gsk, Research Triangle Park, Nc, USA
,
M Gilson
8
Respiratory Research and Development, Gsk, Stockley Park, Uxbridge, Middlesex, UK
,
J H Bentley
9
Clinical Statistics, Gsk, Stockley Park, Uxbridge, Middlesex, UK
,
E S Bradford
10
Respiratory Therapeutic Area, Gsk, Research Triangle Park, Nc, USA
,
S W Yancey
10
Respiratory Therapeutic Area, Gsk, Research Triangle Park, Nc, USA
› Author Affiliations
